Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
US-2024041933-A1 · Feb 8, 2024 · US
US12129487B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12129487-B2 |
| Application number | US-201816498803-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 26, 2018 |
| Priority date | Mar 27, 2017 |
| Publication date | Oct 29, 2024 |
| Grant date | Oct 29, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a method for preparing lymphoid progenitors. The inventors took advantage of their original and relevant Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome (WS) model and the access to blood samples from five WS patients to investigate the impact of CXCR4 desensitization on BM and extra-medullary (i.e. splenic) hematopoiesis and hematopoietic stem and progenitor cells (HSPCs) recirculation. They developed, for the first time, an original in vitro system permitting to selectively expand HSPCs to obtain lymphoid progenitors by using an original cocktail of cytokines. In particular, the present invention relates to an in vitro method for preparing lymphoid progenitors by culturing HSPCs in an appropriate culture medium comprising an effective amount of a cocktail of cytokines consisting in SCF, IL-3, IL-6, IL-7, Flt-3, and CXCL12.
Opening claim text (preview).
The invention claimed is: 1. A method of differentiating hematopoietic stem and progenitor cells (HSPCs) into lymphoid progenitor cells, said method comprising culturing the HSPCs in vitro in a culture medium comprising a cocktail of cytokines consisting of SCF, IL-3, IL-6, IL-7 and Flt-3, wherein the cytokines are present in an amount sufficient to cause differentiation of the HSPCs into lymphoid progenitor cells. 2. A method of differentiating hematopoietic stem and progenitor cells (HSPCs) into lymphoid progenitor cells, said method comprising culturing the HSPCs in vitro in a culture medium comprising a cocktail of cytokines consisting of SCF, IL-3, IL-6, IL-7 and Flt-3, and chemokine CXCL12, wherein the cytokines and the chemokine CXCL12 are present in an amount sufficient to cause differentiation of the HSPCs into lymphoid progenitor cells.
B lymphocytes · CPC title
T lymphocytes · CPC title
Flt-3 ligand (CD135L, flk-2 ligand) · CPC title
Interleukin-7 (IL-7) · CPC title
Interleukin-6 (IL-6) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.